XyloCor Therapeutics
With more than 25 years of experience in the biopharmaceutical industry, Alex Gaidamaka has a wealth of biologics R&D expertise including preclinical, process & analytical development, GMP manufacturing and validations. He also has significant regulatory experience across multiple technology platforms from his tenures with Sanofi Group, AmpliPhi Biosciences, Personalized Onco Therapeutics Inc. and other companies. Dr. Gaidamaka has a PhD in immunology and microbiology and is a Doctor of Veterinary Medicine.
This person is not in any offices
XyloCor Therapeutics
XyloCor Therapeutics is a development-stage, biotechnology company dedicated to developing first-in-class gene therapies for patients with unmet medical need in cardiovascular disease.